WO2010066709A1

WO2010066709A1 - Novel pyridinyl acrylamide derivatives

Info

Publication number: WO2010066709A1
Application number: PCT/EP2009/066585
Authority: WO
Inventors: Fredrik Björkling; Mette Knak Christensen
Original assignee: Topotarget A/S
Priority date: 2008-12-09
Filing date: 2009-12-08
Publication date: 2010-06-17

Abstract

The present application discloses pyridinyl acrylamide derivatives of the formula (I) wherein X is opt.subst. pyrid-3-yl, pyrid-4-yl; A is -C(=O)-, -S(=O)2-, -C(=S)-, -P(=O)(R⁵)- (R⁵ is C_1-6-alkyl, C_1-6-alkoxy, hydroxy); B is a single bond, -O-; D is a single bond, -O-, -CR⁷R⁸-, -NR⁹-; m is 0-12, n is 0-12, m+n is 1-20. The compounds are useful for the inhibiting of the enzyme nicotinamide phosphoribosyltransferase (NAMPRT), and to medical use of such pyridinyl acrylamide derivatives.

Description

NOVEL PYRIDINYL ACRYLAMIDE DERIVATIVES

FIELD OF THE INVENTION

The present invention relates to pyridinyl acrylamide derivatives which are useful for the inhibiting of the enzyme nicotinamide phosphoribosyltransferase (NAMPRT), and to medical use of such pyridinyl acrylamide derivatives.

BACKGROUND OF THE INVENTION

Inhibition of the enzyme nicotinamide phosphoribosyltransferase (NAMPRT) results in the inhibition of NF-kB, the inhibition of NF-kB being a result of the lowering of cellular concentrations of nicotinamide adenine dinucleotide (NAD) (Beauparlant et al (2007) AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2007 Oct 22-26 Abstract nr A82; and Roulson et al (2007) AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2007 Oct 22-26 Abstract nr A81). Tumor cells have elevated expression of NAMPRT and a high rate of NAD turnover due to high ADP-ribosylation activity required for DNA repair, genome stability, and telomere maintenance making them more susceptible to NAMPRT inhibition than normal cells. This also provides a rationale for the use of compounds of this invention in combination with DNA damaging agents for future clinical trials.

The pathways of NAD biosynthesis are shown in Figure 1.

NAMPRT is involved in the biosynthesis of nicotinamide adenine dinucleotide (NAD) and NAD(P). NAD can be synthesized in mammalian cells by three different pathways starting either from tryptophan via quinolinic acid, from nicotinic acid (niacin) or from nicotinamide (niacinamide).

Quinolinic acid reacts with phosphoribosyl pyrophosphate to form niacin mononucletide (dNAM) using the enzyme quinolinic acid phosphoribosyltransferase θ which is found in liver kidney and brain.

Nicotinic acid (niacin) reacts with PRPP to form niacin mononucleotide (dNAM), using the enzyme niacin phosphoribosyltransferase θ which is widely distributed in various tissues. Nicotinamide (niacinamide) reacts with PRPP to give niacinamide mononucleotide (NAM) using the enzyme nicotinamide phosphoribosyltransferase (NAMPRT) O which is also widely distributed in various tissues.

The subsequent addition of adenosine monophosphate to the mononucleotides results in the formation of the corresponding dinucleotides: Niacin mononucleotide and niacinamide mononucleotide react with ATP to form niacin adenine dinucleotide (dNAD) and niacinamide adenine dinucleotide (NAD) respectively. Both reactions, although they take place on different pathways, are catalysed by the same enzyme, NAD pyrophosphorylase O.

A further amidation step is required to convert niacin adenine dinucleotide (dNAD) to niacinamide adeinine dinucleotide (NAD) The enzyme which catalyses this reaction is NAD synthetase θ. NAD is the immediate precursor of niacinamide adenine dinucleotide phosphate (NAD(P)) The reaction is catalysed by NAD kinase. For details see, e.g., Cory J. G. Purine and pyrimidine nucleotide metabolism In: Textbook of Biochemistry and Clinical Correlations 3^rd edition ed. Devlin, T, Wiley, Brisbane 1992, pp 529-574.

Normal cells can typically utilize both precursors niacin and niacinamide for NAD(P) synthesis, and in many cases additionally tryptophan or its metabolites. Accordingly, murine glial cells use niacin, niacinamide and quinolinic acid (Grant et al. (1998) J. Neurochem. 70: 1759- 1763). Human lymphocytes use niacin and niacinamide (Carson et al (1987) J. Immunol. 138: 1904-1907; Berger et al (1982) Exp. Cell Res. 137; 79-88). Rat liver cells use niacin, niacinamide and tryptophan (Yamada et al (1983) Int. J. Vit. Nutr. Res. 53: 184-1291; Shin et al (1995) Int. J. Vit. Nutr. Res. 65: 143-146; Dietrich (1971) Methods Enzymol. 18B; 144- 149). Human erythrocytes use niacin and niacinamide (Rocchigiani et al (1991) Purine and pyrimidine metabolism in man VII Part B ed. Harkness et al Plenum Press New York pp337- 3490). Leukocytes of guinea pigs use niacin (Flechner et al (1970), Life Science 9: 153-162).

NAD(P) is involved in a variety of biochemical reactions which are vital to the cell and have therefore been thoroughly investigated. The role of NAD(P) in the development and growth of tumours has also been studied. It has been found that many tumour cells utilize niacinamide for cellular NAD(P) synthesis. Niacin and tryptophan which constitute alternative precursors in many normal cell types cannot be utilized in tumour cells, or at least not to an extent sufficient for cell survival. Selective inhibition of an enzyme which is only on the niacinamide pathway (such as NAMPRT) would constitute a method for the selection of tumour specific drugs. This has been exemplified by the NAMPRT inhibitor APO866. (see Hasmann and Schemainda, Cancer Res 63(21) :7463-7442.) It is known that various derivatives of pyridinyl acrylamide, substituted in a specific manner have pharmacologically useful properties. In particular, certain derivatives are known to possess therapeutic activity. All of these compounds however are structurally dissimilar from the compounds of the present invention.

Biedermann et al. (1999) describe the following compounds as potential antiproliferative agents in patent applications WO 99/53920, WO 99/31064 and WO 99/31063:

Arai et al. (2000) describe the following compound as binding to the nociceptin receptor in patent application WO 2002/026714:

SUMMARY OF THE INVENTION

It is believed that the novel compounds of the invention are acting on the enzyme nicotinamide phosphoribosyltransferase (NAMPRT), and that the down-stream inhibition of NF-kB is the result of the lowering of cellular concentrations of nicotinamide adenine dinucleotide (NAD).

Hence, the present invention provides compounds of the general formula (I) according to claim 1, and the utilization of these compounds in medicine, cf. claims 14-20.

Inhibitors of the enzyme NAMPRT may be used in the treatment of cancer (WO 97/48696), to cause immuno-suppression (WO 97/48397), for the treatment of diseases involving angiogenesis (WO 2003/80054), for the treatment of rheumatoid arthritis or septic shock (WO 2008/025857), or for the prophylaxis and treatment of ischaemia (WO 2009/109610).

BRIEF DESCRIPTION OF THE FIGURE

Figure 1 illustrates the pathway of NAD biosynthesis (from Biedermann E. et al, WO 2000/50399).

DETAILED DISCLOSURE OF THE INVENTION

Compounds of the invention

The present invention i.a. relates to particular pyridinylacrylamide derivatives which are useful for the inhibition of the enzyme nicotinamide phosphoribosyltransferase (NAMPRT). The present invention relates to compounds of the formula (I)

wherein

X is selected from optionally substituted pyrid-3-yl and optionally substituted pyrid-4-yl;

A is selected from -C(=O)-, -S(=O)₂-, -C(=S)- and -P(=O)(R⁵)-, wherein R⁵ is selected from Ci-₆-alkyl, Ci-₆-alkoxy and hydroxy;

B is selected from a single bond and -O-;

D is selected from a single bond, -O-, -CR⁷R⁸-, -NR⁹-, wherein R⁷, R⁸ and R⁹ are independently selected from hydrogen, optionally substituted Ci-i₂-alkyl, optionally substituted Ci-i₂-alkenyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl;

m is an integer of 0-12 and n is an integer of 0-12, wherein the sum m+n is 1-20;

R¹ and R² are independently selected from hydrogen, optionally substituted Ci-i₂-alkyl, optionally substituted C₃-i₂-cycloalkyl, -[CH₂CH₂O]i-i₀-(optionally substituted Ci-₆-alkyl), optionally substituted Ci_i₂-alkenyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; and R³ is selected from optionally substituted Ci_i₂-alkyl, optionally substituted C₃-i₂-cycloalkyl, -[CH₂CH₂O]i-i₀-(optionally substituted Ci-₆-alkyl), optionally substituted Ci_i₂-alkenyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; or R² and R³ together with the intervening atoms {i.e. -N-B-) form an optionally substituted N-containing heterocyclic or heteroaromatic ring; and

each of R⁴ and R^4* is independently selected from hydrogen, optionally substituted Ci_i₂-alkyl and optionally substituted Ci_i₂-alkenyl.

In particular, when X is pyrid-3-yl, R¹ is hydrogen, m+n is 2, R⁴ and R^4* are both hydrogen, D is a single bond and A is selected from -C(=O)- and -S(=O)₂-, then -NR²BR³ is not N¹- diphenylmethyl-piperazine; and when X is pyrid-3-yl, R¹ is hydrogen, m+n is 1, R⁴ and R^4* are both hydrogen, D is a single bond, and A is -C(=O)-, and R² is hydrogen, then R³ is not 1-propyl- spiro[lH}-indene-l,4'-piperidine:

In addition, when X = unsubstituted pyrid-3-yl and D = -NR -, then B = -O-.

Definitions

In the present context, the terms "Ci-i₂-alkyl" and "Ci-₆-alkyl" are intended to mean a linear, cyclic or branched hydrocarbon group having 1 to 12 carbon atoms and 1 to 6 carbon atoms, respectively, such as methyl, ethyl, propyl, /so-propyl, cyclopropyl, butyl, /so-butyl, tert- butyl, cyclobutyl, pentyl, cyclopentyl, hexyl, and cyclohexyl.

Although the term "C₃-i₂-cycloalkyl" is encompassed by the term "Ci-i₂-alkyl", it refers specifically to the mono- and bicyclic counterparts, including alkyl groups having exo-cyclic atoms, e.g. cyclohexyl -methyl.

Similarly, the terms "C₂-i₂-alkenyl" and "C₂-₆-alkenyl" are intended to cover linear, cyclic or branched hydrocarbon groups having 2 to 12 carbon atoms and 2 to 6 carbon atoms, respectively, and comprising (at least) one unsaturated bond. Examples of alkenyl groups are vinyl, ally I, butenyl, pentenyl, hexenyl, heptenyl, octenyl, heptadecaenyl. Preferred examples of alkenyl are vinyl, allyl, butenyl, especially allyl.

Although the term "C₃-i₂-cycloalkenyl" is encompassed by the term "C₂-i₂-alkenyl", it refers specifically to the mono- and bicyclic counterparts, including alkenyl groups having exo-cyclic atoms, e.g. cyclohexenyl -methyl and cyclohexyl-allyl.

In the present context, i.e. in connection with the terms "alkyl", "cycloalkyl", "alkoxy", "alkenyl", "cycloalkenyl" and the like, the term "optionally substituted" is intended to mean that the group in question may be substituted one or several times, preferably 1-3 times, with group(s) selected from hydroxy (which when bound to an unsaturated carbon atom may be present in the tautomeric keto form), Ci-₆-alkoxy {i.e. Ci-₆-alkyl-oxy), C₂-₆-alkenyloxy, carboxy, oxo (forming a keto or aldehyde functionality), Ci-₆-alkoxycarbonyl, Ci_-6- alkylcarbonyl, formyl, aryl, aryloxy, arylamino, arylcarbonyl, aryloxycarbonyl, arylcarbonyloxy, arylaminocarbonyl, arylcarbonylamino, heteroaryl, heteroaryloxy, heteroarylamino, heteroarylcarbonyl, heteroaryloxycarbonyl, heteroarylcarbonyloxy, heteroarylaminocarbonyl, heteroarylcarbonylamino, heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylcarbonyloxy, heterocyclylaminocarbonyl, heterocyclylcarbonylamino, amino, mono- and di(Ci-₆- alkyl)amino, -N(Ci-₄-alkyl)₃ ⁺, carbamoyl, mono- and di(Ci-₆-alkyl)aminocarbonyl, Ci-₆-alkyl- carbonylamino, cyano, guanidino, carbamido, Ci-₆-alkyl-sulphonyl-amino, aryl-sulphonyl- amino, heteroaryl-sulphonyl-amino, Ci-₆-alkanoyloxy, Ci-₆-alkyl-sulphonyl, Ci-₆-alkyl- sulphinyl, Ci-₆-alkylsulphonyloxy, nitro, Ci-₆-alkylthio, and halogen, where any aryl, heteroaryl and heterocyclyl may be substituted as specifically described below for aryl, heteroaryl and heterocyclyl, and any alkyl, alkoxy, and the like, representing substituents may be substituted with hydroxy, Ci-₆-alkoxy, amino, mono- and di(Ci-₆-alkyl)amino, carboxy, Ci-₆-alkylcarbonylamino, Ci-₆-alkylaminocarbonyl, or halogen(s).

Typically, the substituents are selected from hydroxy (which when bound to an unsaturated carbon atom may be present in the tautomeric keto form), Ci-₆-alkoxy {i.e. Ci-₆-alkyl-oxy), C₂-₆-alkenyloxy, carboxy, oxo (forming a keto or aldehyde functionality), Ci-₆-alkylcarbonyl, formyl, aryl, aryloxy, arylamino, arylcarbonyl, heteroaryl, heteroaryloxy, heteroarylamino, heteroarylcarbonyl, heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylcarbonyl, amino, mono- and di(Ci-₆-alkyl)amino; carbamoyl, mono- and di(Ci-₆-alkyl)aminocarbonyl, amino-Ci-₆-alkyl-aminocarbonyl, mono- and di(Ci-₆-alkyl)amino-Ci-₆-alkyl-aminocarbonyl, Ci-₆-alkylcarbonylamino, guanidino, carbamido, Ci-₆-alkyl-sulphonyl-amino, Ci-₆-alkyl- sulphonyl, Ci-₆-alkyl-sulphinyl, Ci-₆-alkylthio, halogen, where any aryl, heteroaryl and heterocyclyl may be substituted as specifically described below for aryl, heteroaryl and heterocyclyl.

In some embodiments, substituents are selected from hydroxy, Ci-₆-alkoxy, amino, mono- and di(Ci-₆-alkyl)amino, carboxy, Ci-₆-alkylcarbonylamino, Ci-₆-alkylaminocarbonyl, or halogen.

The term "halogen" includes fluoro, chloro, bromo, and iodo.

In the present context, the term "aryl" is intended to mean a fully or partially aromatic carbocyclic ring or ring system, such as phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, anthracyl, phenanthracyl, pyrenyl, benzopyrenyl, fluorenyl and xanthenyl, among which phenyl is a preferred example.

The term "heteroaryl" is intended to mean a fully or partially aromatic carbocyclic ring or ring system where one or more of the carbon atoms have been replaced with heteroatoms, e.g. nitrogen ( = N- or -NH-), sulphur, and/or oxygen atoms. Examples of such heteroaryl groups are oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, coumaryl, furanyl, thienyl, quinolyl, benzo- thiazolyl, benzotriazolyl, benzodiazolyl, benzooxozolyl, phthalazinyl, phthalanyl, triazolyl, tetrazolyl, isoquinolyl, acridinyl, carbazolyl, dibenzazepinyl, indolyl, benzopyrazolyl, phenoxazonyl. Particularly interesting heteroaryl groups are benzimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, furyl, thienyl, quinolyl, triazolyl, tetrazolyl, isoquinolyl, indolyl in particular benzimidazolyl, pyrrolyl, imidazolyl, pyridinyl, pyrimidinyl, furyl, thienyl, quinolyl, tetrazolyl, and isoquinolyl.

The term "heterocyclyl" is intended to mean a non-aromatic carbocyclic ring or ring system where one or more of the carbon atoms have been replaced with heteroatoms, e.g. nitrogen ( = N- or -NH-), sulphur, and/or oxygen atoms. Examples of such heterocyclyl groups (named according to the rings) are imidazolidine, piperazine, hexahydropyridazine, hexahydro- pyrimidine, diazepane, diazocane, pyrrolidine, piperidine, azepane, azocane, aziridine, azirine, azetidine, pyroline, tropane, oxazinane (morpholine), azepine, dihydroazepine, tetrahydroazepine, and hexahydroazepine, oxazolane, oxazepane, oxazocane, thiazolane, thiazinane, thiazepane, thiazocane, oxazetane, diazetane, thiazetane, tetrahydrofuran, tetrahyd ropy ran, oxepane, tetrahydrothiophene, tetrahydrothiopyrane, thiepane, dithiane, dithiepane, dioxane, dioxepane, oxathiane, oxathiepane. The most interesting examples are tetrahydrofuran, imidazolidine, piperazine, hexahydropyridazine, hexahydropyrimidine, diazepane, diazocane, pyrrolidine, piperidine, azepane, azocane, azetidine, tropane, oxazinane (morpholine), oxazolane, oxazepane, thiazolane, thiazinane, and thiazepane, in particular tetrahydrofuran, imidazolidine, piperazine, hexahydropyridazine, hexahydropyrimidine, diazepane, pyrrolidine, piperidine, azepane, oxazinane (morpholine), and thiazinane.

The term "N-containing heterocyclic or heteroaromatic ring" are intended to encompass those mentioned under "heterocyclyl" and "heteroaryl", respectively, which include one or more heteroatoms, at least one of which begin a nitrogen atom. Examples hereof are piperazine, isoxazole, isoxazolidine, and morpholine, etc. The term "N,O-containing heterocyclic or heteroaromatic ring" are intended to encompass those mentioned under "heterocyclyl" and "heteroaryl", respectively, which include two or more heteroatoms, two of which being neighbouring nitrogen and oxygen atoms. Examples hereof are isoxazole, isoxazolidine, morpholine, etc.

In the present context, i.e. in connection with the terms "pyrid-3-yl", "pyrid-4-yl", "aryl",

"heteroaryl", "heterocyclyl", "N,O-containing heterocyclic or heteroaromatic ring" and the like (e.g. "aryloxy", "heterarylcarbonyl", etc.), the term "optionally substituted" is intended to mean that the group in question may be substituted one or several times, preferably 1-5 times, in particular 1-3 times, with group(s) selected from hydroxy (which when present in an enol system may be represented in the tautomeric keto form), Ci-₆-alkyl, Ci-₆-alkoxy, C_2-6- alkenyloxy, oxo (which may be represented in the tautomeric enol form), oxide (only relevant as the N-oxide), carboxy, Ci-₆-alkoxycarbonyl, Ci-₆-alkylcarbonyl, formyl, aryl, aryloxy, arylamino, aryloxycarbonyl, arylcarbonyl, heteroaryl, heteroarylamino, amino, mono- and di(Ci-₆-alkyl)amino; carbamoyl, mono- and di(Ci-₆-alkyl)aminocarbonyl, amino-Ci-₆-alkyl- aminocarbonyl, mono- and di(Ci-₆-alkyl)amino-Ci-₆-alkyl-aminocarbonyl, Ci-₆-alkylcarbony- lamino, cyano, guanidino, carbamido, Ci-₆-alkanoyloxy, Ci-₆-alkyl-sulphonyl-amino, aryl- sulphonyl-amino, heteroaryl-sulphonyl-amino, Ci-₆-alkyl-suphonyl, Ci-₆-alkyl-sulphinyl, Ci_-6- alkylsulphonyloxy, nitro, sulphanyl, amino, amino-sulfonyl, mono- and di(Ci-₆-alkyl)amino- sulfonyl, dihalogen-Ci-₄-alkyl, trihalogen-Ci-₄-alkyl, halogen, where aryl and heteroaryl representing substituents may be substituted 1-3 times with Ci-₄-alkyl, Ci-₄-alkoxy, nitro, cyano, amino or halogen, and any alkyl, alkoxy, and the like, representing substituents may be substituted with hydroxy, Ci-₆-alkoxy, C₂-₆-alkenyloxy, amino, mono- and di(Ci_₆- alkyl)amino, carboxy, Ci-₆-alkylcarbonylamino, halogen, Ci-₆-alkylthio, Ci-₆-alkyl-sulphonyl- amino, or guanidino.

Typically, the substituents are selected from hydroxy, Ci-₆-alkyl, Ci-₆-alkoxy, oxo (which may be represented in the tautomeric enol form), carboxy, Ci-₆-alkylcarbonyl, formyl, amino, mono- and di(Ci-₆-alkyl)amino; carbamoyl, mono- and di(Ci-₆-alkyl)aminocarbonyl, amino- Ci-₆-alkyl-aminocarbonyl, Ci-₆-alkylcarbonylamino, guanidino, carbamido, Ci-₆-alkyl- sulphonyl-amino, aryl-sulphonyl-amino, heteroaryl-sulphonyl-amino, Ci-₆-alkyl-suphonyl, Ci-₆-alkyl-sulphinyl, Ci-₆-alkylsulphonyloxy, sulphanyl, amino, amino-sulfonyl, mono- and di(Ci-₆-alkyl)amino-sulfonyl or halogen, where any alkyl, alkoxy and the like, representing substituents may be substituted with hydroxy, Ci-₆-alkoxy, C₂-₆-alkenyloxy, amino, mono- and di(Ci-₆-alkyl)amino, carboxy, Ci-₆-alkylcarbonylamino, halogen, Ci-₆-alkylthio, Ci-₆-alkyl- sulphonyl-amino, or guanidino. In some embodiments, the substituents are selected from Ci-₆-alkyl, Ci-₆-alkoxy, amino, mono- and di(Ci-₆-alkyl)amino, sulphanyl, carboxy or halogen, where any alkyl, alkoxy and the like, representing substituents may be substituted with hydroxy, Ci-₆-alkoxy, C₂-₆-alkenyloxy, amino, mono- and di(Ci-₆-alkyl)amino, carboxy, Ci_-6- alkylcarbonylamino, halogen, Ci-₆-alkylthio, Ci-₆-alkyl-sulphonyl-amino, or guanidino.

Groups (e.g. R² and R³) including C₃-i₂-cycloalkyl, C₃-i₂-cycloalkenyl and/or aryl as at least a part of the substituent are said to include "a carbocyclic ring".

Groups {e.g. R² and R³) including heterocyclyl or heteroaryl as at least a part of the substituent are said to include "a heterocyclic ring" and "a heteroaromatic ring", respectively.

The term "pharmaceutically acceptable salts" is intended to include acid addition salts and basic salts. Illustrative examples of acid addition salts are pharmaceutically acceptable salts formed with non-toxic acids. Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromotheophylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric acids. Examples of basic salts are salts where the (remaining) counter ion is selected from alkali metals, such as sodium and potassium, alkaline earth metals, such as calcium, and ammonium ions (⁺N(R)₃R', where R and R' independently designates optionally substituted Ci-₆-alkyl, optionally substituted C_2-6- alkenyl, optionally substituted aryl, or optionally substituted heteroaryl). Pharmaceutically acceptable salts are, e.g., those described in Remington's Pharmaceutical Sciences, 17. Ed. Alfonso R. Gennaro (Ed.), Mack Publishing Company, Easton, PA, U.S.A., 1985 and more recent editions and in Encyclopedia of Pharmaceutical Technology. Thus, the term "an acid addition salt or a basic salt thereof" used herein is intended to comprise such salts. Furthermore, the compounds as well as any intermediates or starting materials may also be present in hydrate form.

The term "prodrug" used herein is intended to mean a compound which - upon exposure to physiological conditions - will liberate a derivative said compound which then will be able to exhibit the desired biological action. Typical examples are labile esters (i.e. a latent hydroxyl group or a latent acid group).

Moreover, it should be understood that the compounds may be present as racemic mixtures or the individual stereoisomers such as enantiomers or diastereomers. The present invention encompasses each and every of such possible stereoisomers (e.g. enantiomers and diastereomers) as well as racemates and mixtures enriched with respect to one of the possible stereoisomers.

Embodiments

In one primary embodiment, X is optionally substituted pyrid-3-yl, in particular pyrid-3-yl.

In another embodiment, X is optionally substituted pyrid-4-yl, in particular pyrid-4-yl.

In one embodiment hereof, B is -O-. Within one important variant of this embodiment A is -S(=O)₂-. Within another important variant of this embodiment, A is -C(=O)-.

In another embodiment, B is a single bond. Within one important variant of this embodiment A is -S(=O)₂-. Within another important variant of this embodiment, A is -C(=O)-.

In the above embodiments, D is preferably selected from a single bond and -O-. More particular, D is a single bond.

In an alternative embodiment, D is -NR⁹-.

In particular, if A is -C(=O)-, B is preferably not a single bond.

The length of the spacer element is defined by m and n. Preferably, m is an integer of 0-10 and n is an integer of 0-10, wherein the sum m+n is 1-12; in particular m is an integer of 1- 8 and n is an integer of 0-3, wherein the sum m+n is 3-8. In a currently most preferred variant, m is an integer of 2-8, in particular 3-7, such as 4-6, and n is 0.

It is currently very preferred that the sum m+n is 3-6.

It appears that - besides D, A and B - R² and R³ (and in part also R⁴ and R^4*) play an important role for the efficacy of the compounds of the invention. Hence, in one particularly interesting embodiment, at least one of R² and R³ includes a carbocyclic ring, heterocyclic ring or a heteroaromatic ring, or R² and R³ together with the intervening atoms form an optionally substituted N-containing heterocyclic or heteroaromatic ring, however preferably not an optionally substituted piperazine ring. In a particularly interesting variant of this embodiment R² includes a carbocyclic ring, such as a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl ring, in particular R² include a cyclohexyl ring. In one variant hereof, R² and R³ together with the intervening atoms form an optionally substituted N,O-containing heterocyclic or heteroaromatic ring.

In some other currently preferred embodiments, R² is not hydrogen.

In some embodiments, R³ is C₂-₅-alkyl substituted with either a C₄-₇-cycloalkyl ring or a heterocyclyl ring.

Moreover, R⁴ is preferably selected from hydrogen, Ci-₆-alkyl and optionally substituted benzyl and R^4* is hydrogen. More particular, R⁴ and R^4* are preferably both hydrogen.

In one currently particularly relevant embodiment,

A is selected from -C(=O)- and -S(=O)₂-;

B is -O-;

D is selected from a single bond and -O-,

m is an integer of 2-8 and n is 0;

R² and R³ together with the intervening atoms form an optionally substituted N-containing heterocyclic or heteroaromatic ring; and

R⁴ and R^4* are hydrogen.

In another currently particularly relevant embodiment,

A is selected from -C(=O)- and -S(=O)₂-;

B is -O-;

D is selected from a single bond and -O-, m is an integer of 2-8 and n is 0;

R² is selected from hydrogen, optionally substituted C₃-i₂-cycloalkyl, -[CH₂CH₂O]i-i₀- (optionally substituted Ci-₆-alkyl), -(CH₂)o-₂-(optionally substituted aryl), -(CH₂)₀-₂-(optionally substituted heteroaryl) and -(CH₂)₀-₂-(optionally substituted heterocyclyl);

R³ is selected from optionally substituted C₃-i₂-cycloalkyl, -[CH₂CH₂O]i-i₀-(optionally substituted Ci-₆-alkyl), optionally substituted Ci_i₂-alkenyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl;

R⁴ is selected from hydrogen, optionally substituted C₃-i₂-cycloalkyl, -(CH₂)₀-₂-(optionally substituted aryl), -(CH₂)₀-₂-(optionally substituted heteroaryl) and -(CH₂)₀-₂-(optionally substituted heterocyclyl); and

R is hydrogen.

This being said, currently most interesting compounds are those selected from compounds 1001-1038 described in the following :

General Syntheses

The compounds of the present invention can be synthesized using the methods outlined below, together with methods known in the art of synthetic organic chemistry, or variations thereof as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below.

The novel compounds of formula (I) may be prepared using the reactions and techniques described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and suitable for the transformations being effected. Also, in the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature duration of experiment and work-up procedures, are chosen to be conditions of standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the educt molecule must be compatible with the reagents and reactions proposed. Not all molecules of formula (I) falling into a given class may be compatible with some of the reaction conditions required in some of the methods described. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternative methods can be used.

Compounds (I) according to the present invention can be prepared in several ways, e.g. by coupling acid of general formula (II) with amines of general formula (III) using a peptide coupling reagent, e.g. EDC or HATU.

(II) (III) (I)

Amines of general formula (III), which are hydroxamic acid esters, Λ/-alkyl- or N- arylhydrazides, Λ/,Λ/ ^'-dialkyl- or Λ/,Λ/ ^'-diarylhydrazides (Ilia) can be prepared from protected amino acids of general formula (IV) (protecting group Pg e.g. Boc or phtalimido) by coupling with hydroxylamines or hydrazines of general formula (V) using a peptide coupling reagent (e.g. EDC or HATU), and subsequent removal of the protecting group.

O₁ NR⁶

In the special case where amines of general formula (Ilia) contain a substituent α to the carbonyl group they can be prepared from amino acids of general formula (VII) or their enantiomers (obtained as described in the literature e.g K. S. Orwig et al. : Tet.Lett. (2005) 46 7007-7009), followed by protection of the amino group {e.g. with Boc or phtalimido) and subsequent coupling with hydroxylamines or hydrazines followed by deprotection as described above.

(VII) (IVa)

Hydroxylamines (V, B = O)) are either commercially available or can be prepared from N- hydroxyphtalimide (or alternatively tert-butylhydroxycarbamate) by alkylation with a halogenide and a base (e.g. DBU) or a Mitsunobu reaction with an alcohol (using e.g. DEAD), followed by deprotection with hydrazine or methylhydrazine, resulting in hydroxylamine (Villa). When R² is hydrogen, the resulting hydroxylamine (Va) may be subject to reductive amination with an aldehyde or ketone followed by reduction with e.g. sodium cyanoborohydride as described in the literature {e.g. B.J. Mavunkel et al. \ Eur.J.Med.Chem. (1994) 29, 659-666; T. Ishikawa et.al.: J.Antibiotics (2000), 53 (10), 1071-1085; J.Ishwara Bhat et al. : J.Chem.Soc, Perkin Trans. 2 (2000), 1435-1446). Alternatively, alkylation of the hydroxylamine (Va) can be achieved by a Mitsunobu reaction or alkylation after protection with e.g. 2-nitrophenylsulfonylchloride and subsequent removal of the protecting group (using e.g. thiophenol and cesium carbonate).

O R³ ° NH_{2 + R}A_R2 R³ <V "R² ^R2 N %³ H

Hydrazines (V, B=N) are either commercially available or can - in the case where R² is H - be prepared from hydrazine hydrate by alkylation in the presence of a base according to literature procedures (e.g. DJ. Drain et al.: J.Med.Chem. (1963) 6 63-9; G. B. Marini-Bettolo et al.: Rend.Ist.Super.Sanita (1960) 23 1110-27). N, N ^'-Disubstituted hydrazines can be obtained from monosubstituted hydrazines (Va) by reaction with an aldehyde or ketone followed by redcuction with e.g. hydrogen, LiAIH₄, or borane according to literature procedures (e.g. H.Dorn et.al. : Zeitschrift fur Chemie (1972) 12(4) 129-30; R. L. Hinman: JACS (1957) 79 414-417; J.A.Blair: JCS (Section) C: Organic (1970) (12) 1714-17) or alternatively by Boc-protection of hydrazine hydrate, alkylation with an alkylhalogenide in the presence of sodium hydride, followed by a second alkylation with another alkylhalogenide in the presence of sodium hydride and finally removal of the Boc-protecting groups (L.Ling et al.:Bioorg. Med. Chem. Lett. (2001) (11) 2715-2717). Base

N₂H₄ H₂O + R³-X ^R2 _\=_N N _R3 ™°" _R2 H

H₂N " R³ R R^ N H

(Va) (V)

(BoC)₂O NaH, R²-X NaH, R³-X „ , HCI _R2 tj

N₂H₁ H₂O BocNHNHBoc BocNR²NHBoc L» ^" BocNR²NHR³Boc N R³ H

(V)

Amines of general formula (III), which are Λ/-alkoxy- or Λ/-aryloxythioamides, or thiohydrazides (HIb) can be prepared from the corresponding carbonyl compounds (Ilia) by treatment with Lawesson reagent according to literature procedures (e.g. Thomsen et al.: Org. Synth. (1984) 62, 158, R.A. Cherkasov et al.: Tet. (1985) 41, 2567; M. P. Cava, MJ. Levinson Tet. (1985) 41, 5061).

(MIa) B = O₁ NR⁶ (MIb) B = O₁ NR⁶

Alternatively, protected amino acids of general formula (IV) (protecting group e.g. Boc or phtalimido) can be converted into an activated species of general formula (VIII) according to literature procedures (M. A: Shalaby et al.: J.Org.Chem. (1996) 61 9045-48) and subsequently allowed to react with hydroxylamines or hydrazines of general formula (V) followed by deprotection to yield amines of general formula (HIb).

(1Mb)

Amines of general formula (III), which are Λ/-alkoxy or Λ/-aryloxy sulfonamides, sulfonamides or sulfonylhydrazides (HIc) can be obtained by reaction of phtalimidoalkanesulfonylchlorides (IX) (prepared as described in the literature, e.g. GJ. Atwell et al. : J.Med.Chem. (1977) 20(9) 1128-134; J. Humljan et al.i: Tet.Letters, 46 4069-4072) with hydroxylamines, amines or hydrazines (VIII), respectively, in the presence of a base {e.g. triethyamine or N- methylmorpholine^ followed by deprotection with hydrazine hydrate. Other protecting groups than phtalimido may be used.

i °

Amines of general formula (III) which are Λ/-alkoxy-P-alkylphosphonamidates or Λ/-aryloxy-P- alkylphosphonamidates, P-alkylphosphonamidates or P-alkylphosphonohydrazidates (HId) can be obtained by reaction of the phtalimido protected phosphonochloridates (X) (prepared as described in the literature, e.g. S.Gobecet al.: TeL Lett. (2002) 43 167-170; U.Urleb et a/./ Lett. In Peptide Science (1995) 2 193-197) with hydroxylamines, amines or hydrazines (V), respectively, in the presence of a base followed by deprotection with hydrazine hydrate. Other protecting groups than phtalimido may be used.

N B R^{3 N}H₂ ^NH₂ H₂ -O. N B R ^K3

Amines of general formula (III) which are Λ/-alkoxy-P-alkylphosphinic amides or Λ/-aryloxy-P- alkylphosphinic amides, P-alkylphosphinic amides or P-akylphosphinic hydrazides (HIe) can be obtained by reaction of the phtalimido protected alkylphosphinic chlorides (XI) {e.g. S. Gobec et al.: Lett. In Peptide Science (1998) 5 109-114) with hydroxylamines, amines or hydrazines (V), respectively, in the presence of a base followed by deprotection with hydrazine hydrate. Other protecting groups than phtalimido may be employed.

O O R² R²

O base mj n P-Cl ^H B

^{" R2} N R³

R⁴ R⁵ H (Vy φ R³ NH₂NH₂ H₂O M ^F ml n H₂N-T ^

R⁴ R⁵ R⁴ R⁵

O O

(Xl) (V) B = O NR⁶ bond (MIe)

Amines of general formula (III) which are sulfonylureas (HIf) can be prepared from known literature procedures {e.g. B. Hόkfelt et al. :J.Med.&Pharm. Chem. (1962) 5 231-9; R. TuII et al. JCS Section CiOrganic (1967) (8) 701-2;B. Loev: J. Med. Chem. (1963) 6(5) 506-8; D.R.Cassady et al. : J.Org.Chem. (1958) 23 923-6; D. Freitag -.Tetrahedron (2005) 61 5615- 21; Y. Kanbe et.al.: Bioorg. Med. Chem. Lett. (2006) 16 4090-94; I. Ubarretxena-Belandia et.al.: Eur.J.Biochem. (1999) 260 794-800; B. D. Roth et al. : Bioorg. Med. Chem. Lett. (1995) 5(20) 2367-70 ), for instance by reaction of suitably protected aminoalkanesulfonylchlorides (IX) with an ammonia equivalent or amine, followed by reaction with an alkyl chloroformate in the presence of a base to yield carbamates of general formula (XIII), which are subsequently allowed to react with amines R³R⁵NH₂ to yield sulfonylureas of general formula (XIV). Alternatively, sulfonamides of general formula (XII) can react directly with isocyanates to yield protected sulfonylureas (XVIIa). The protecting group (e.g phtalimido, Boc or other) is subsequently removed to yield (HIf).

R³ R² R^β

O , NH

R²NH₂ Ll ° n S-Cl ^N mT ViS ^ROCOCI N+Φ+Ss V' ° _R Pg m

R⁴ O ^H R⁴ O R⁴ O O R⁴ ¹ I v O *

R=alkyl (IX) (XII) (XIII) (XIV)

R²

⁰ H [ i ^c

-H- S, ^N R + R³NCO Pg — H₂N^S s¹ ' R⁴ O O R⁴ O O

(XII) (XIVa) (NIf)

Amines of general formula (III) which are Λ/-alkoxy- or Λ/-aryloxy carbamates or alkyl-or arylhydrazinecarboxylates (HIg) can be obtained by reaction of protected aminoalkyl 4- nitrophenyl carbonates (XV) (protecting group e.g. Boc or phtalimido) with hydroxylamines or hydrazines (V) followed by deprotection as depicted below.

NR⁶

R³

(XVI) (ing)

Amines of general formula (III) which are Λ/-alkoxy- or Λ/-aryloxy ureas or alkyl- or arylhydrazinecarboxamides (HIh) can be prepared by methods known to one skilled in the art for preparing ureas. One such method is reaction of protected 4-nitrophenyl aminoalkyl carbamates (XVII) (protecting group e.g. Boc or phtalimido) with hydroxylamines or hydrazines (V) followed by deprotection as depicted below.

NR⁶

HOBt, DIEA Pg , R³

(XVIIi) (IMh)

As an alternative to 4-nitrophenyl aminoalkyl carbamates (XVII), Λ/-(aminoalkyl)-lH- imidazole-l-carboxamides (IXX) may be employed.

(IXX)

Medical uses

The compounds of the invention is believed to be particularly useful for down-regulating NAD via inhibition of NAMPRT, and such compounds are therefore particularly useful for treating diseases in which activation of NF-κB is implicated. Such methods are useful in the treatment of a variety of diseases including inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukaemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, ataxia telengiectasia.

Hence, the present invention provides a compound of the formula (I) for use as a medicament; more particular for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT), especially for the treatment of the above-mentioned diseases and conditions. Moreover, the invention also provides a method of inhibiting the enzymatic activity of nicotinamide phosphoribosyltransferase (NAMPRT) in a mammal, said method comprising the step of administering to said mammal a pharmaceutically relevant amount of a compound of the general formula (I).

Further, the invention provides a method of treating a disease or condition (in particular the diseases and conditions mentioned above) caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT) in a mammal, said method comprising the step of administering to said mammal a pharmaceutically relevant amount of a compound of the general formula (I).

In such methods, the compound may be administered in combination with a DNA damaging agent.

Formulation of pharmaceutical compositions

The compounds of the general formula (I) are suitably formulated in a pharmaceutical composition so as to suit the desirable route of administration.

The administration route of the compounds may be any suitable route which leads to a concentration in the blood or tissue corresponding to a therapeutic effective concentration. Thus, e.g., the following administration routes may be applicable although the invention is not limited thereto: the oral route, the parenteral route, the cutaneous route, the nasal route, the rectal route, the vaginal route and the ocular route. It should be clear to a person skilled in the art that the administration route is dependent on the particular compound in question; particularly the choice of administration route depends on the physico-chemical properties of the compound together with the age and weight of the patient and on the particular disease or condition and the severity of the same.

The compounds may be contained in any appropriate amount in a pharmaceutical composition, and are generally contained in an amount of about 1-95%, e.g. 1-10%, by weight of the total weight of the composition. The composition may be presented in a dosage form which is suitable for the oral, parenteral, rectal, cutaneous, nasal, vaginal and/or ocular administration route. Thus, the composition may be in form of, e.g., tablets, capsules, pills, powders, granulates, suspensions, emulsions, solutions, gels including hydrogels, pastes, ointments, creams, plasters, drenches, delivery devices, suppositories, enemas, injectables, implants, sprays, aerosols and in other suitable form. The pharmaceutical compositions may be formulated according to conventional pharmaceutical practice, see, e.g., "Remington's Pharmaceutical Sciences" and "Encyclopedia of Pharmaceutical Technology", edited by Swarbrick, J. & J. C. Boylan, Marcel Dekker, Inc., New York, 1988. Typically, the compounds defined herein are formulated with (at least) a pharmaceutically acceptable carrier or excipient. Pharmaceutically acceptable carriers or excipients are those known by the person skilled in the art. Formation of suitable salts of the compounds of the Formula (I) will also be evident in view of the before-mentioned.

Thus, the present invention provides in a further aspect a pharmaceutical composition comprising a compound of the general Formula (I) in combination with a pharmaceutically acceptable carrier.

Pharmaceutical compositions according to the present invention may be formulated to release the active compound substantially immediately upon administration or at any substantially predetermined time or time period after administration. The latter type of compositions is generally known as controlled release formulations.

In the present context, the term "controlled release formulation" embraces i) formulations which create a substantially constant concentration of the drug within the body over an extended period of time, ii) formulations which after a predetermined lag time create a substantially constant concentration of the drug within the body over an extended period of time, iii) formulations which sustain drug action during a predetermined time period by maintaining a relatively, constant, effective drug level in the body with concomitant minimization of undesirable side effects associated with fluctuations in the plasma level of the active drug substance (saw-tooth kinetic pattern), iv) formulations which attempt to localize drug action by, e.g., spatial placement of a controlled release composition adjacent to or in the diseased tissue or organ, v) formulations which attempt to target drug action by using carriers or chemical derivatives to deliver the drug to a particular target cell type.

Controlled release formulations may also be denoted "sustained release", "prolonged release", "programmed release", "time release", "rate-controlled" and/or "targeted release" formulations.

Controlled release pharmaceutical compositions may be presented in any suitable dosage forms, especially in dosage forms intended for oral, parenteral, cutaneous nasal, rectal, vaginal and/or ocular administration. Examples include single or multiple unit tablet or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, nanoparticles, liposomes, delivery devices such as those intended for oral, parenteral, cutaneous, nasal, vaginal or ocular use.

Preparation of solid dosage forms for oral use, controlled release oral dosage forms, fluid liquid compositions, parenteral compositions, controlled release parenteral compositions, rectal compositions, nasal compositions, percutaneous and topical compositions, controlled release percutaneous and topical compositions, and compositions for administration to the eye will be well-known to those skilled in the art of pharmaceutical formulation. Specific formulations can be found in "Remington's Pharmaceutical Sciences".

Capsules, tablets and pills etc. may contain for example the following compounds: microcrystalline cellulose, gum or gelatin as binders; starch or lactose as excipients; stearates as lubricants; various sweetening or flavouring agents. For capsules the dosage unit may contain a liquid carrier like fatty oils. Likewise coatings of sugar or enteric agents may be part of the dosage unit. The pharmaceutical compositions may also be emulsions of the compound(s) and a lipid forming a micellular emulsion.

For parenteral, subcutaneous, intradermal or topical administration the pharmaceutical composition may include a sterile diluent, buffers, regulators of tonicity and antibacterials. The active compound may be prepared with carriers that protect against degradation or immediate elimination from the body, including implants or microcapsules with controlled release properties. For intravenous administration the preferred carriers are physiological saline or phosphate buffered saline.

Dosages

In one embodiment, the pharmaceutical composition is in unit dosage form. In such embodiments, each unit dosage form typically comprises 0.1-500 mg, such as 0.1-200 mg, e.g. 0.1-100 mg, of the compound.

More generally, the compound are preferably administered in an amount of about 0.1-250 mg per kg body weight per day, such as about 0.5-100 mg per kg body weight per day.

For compositions adapted for oral administration for systemic use, the dosage is normally 0.5 mg to 1 g per dose administered 1-4 times daily for 1 week to 12 months depending on the disease to be treated. The dosage for oral administration of the composition in order to prevent diseases or conditions is normally 1 mg to 100 mg per kg body weight per day. The dosage may be administered once or twice daily for a period starting 1 week before the exposure to the disease until 4 weeks after the exposure.

For compositions adapted for rectal use for preventing diseases, a somewhat higher amount of the compound is usually preferred, i.e. from approximately 1 mg to 100 mg per kg body weight per day.

For parenteral administration, a dose of about 0.1 mg to about 100 mg per kg body weight per day is convenient. For intravenous administration, a dose of about 0.1 mg to about 20 mg per kg body weight per day administered for 1 day to 3 months is convenient. For intraarticular administration, a dose of about 0.1 mg to about 50 mg per kg body weight per day is usually preferable. For parenteral administration in general, a solution in an aqueous medium of 0.5-2% or more of the active ingredients may be employed.

For topical administration on the skin, a dose of about 1 mg to about 5 g administered 1-10 times daily for 1 week to 12 months is usually preferable.

EXPERIMENTALS

General Procedures, Preparations and Examples

For nuclear magnetic resonance ¹H NMR spectra (300 MHz) and ¹³C NMR (75.6) chemical shift values (δ) (in ppm) are quoted, unless otherwise specified, for deuteriochloroform solutions relative to tetramethylsilane (δ= 0.0) or chloroform (δ = 7.25) or deuteriochloroform (δ =

76.81 for ¹³C NMR) standards. The value of a multiplet, either defined (doublet (d), triplet (t), double doublet (dd), double triplet (dt), quartet (q)) or not (m) at the approximate mid point is given unless a range is quoted, (bs) indicates a broad singlet.

MS was performed using an LC-MS using a Bruker Esquire 3000+ ESI Iontrap with an Agilent 1200 HPLC-system.

The organic solvents used were anhydrous.

The following abbreviations have been used throughout: CDI 1,1 ^'-carbonyldiimidazole

DCM dichloromethane

DCE 1,2-dichloroethane

DIEA diisopropylethylamine

DMF Λ/,Λ/-dinnthylfornnannide

DMAP N, N dimethylaminopyridine

EDC Λ/-(dimethylanninopropyl)-N ^'-ethylcarbodiimide hydrochloride

EtOAc ethyl acetate

HATU O-(7-Azabenzotriazol-l-yl)-Λ/,Λ/,Λ/',Λ/'-tetrannethyluronium hexafluorophosphate

HOBt 1-hydroxybenzotriazole

MS mass spectroscopy

NMM /V-methylmorpholine

NMR nuclear magnetic resonance rt room temperature

THF tetrahydrofurane

TLC thin layer chromatography

General Procedure 1 : Coupling of acids of general formula (II) with amines of general formula (IIP to afford compounds of general formula (I).

Acid of general formula (II) (1 eg.) and amine of general formula (III) were dissolved in DMF. HOBt (1 eg.), NMM (1 eg.) and EDC (1.3 eg.) were added with stirring and the reaction mixture was stirred at rt overnight. The solvent was evaporated in vacuum and the residue was purified by chromatography (chloroform : methanol : NH₃ (25% ag.) 98:2:0.2 to yield compound of general formula (I).

Preparations

Preparation 1 : Λ/-(cyclohexylmethoxy)-5-(l,3-dioxoisoindolin-2-yl)-Λ/-(2-fluoroethyl)pentane- 1-sulfonamide (compound 1).

Λ/-(cyclohexylmethoxy)-5-(l,3-dioxoisoindolin-2-yl)pentane-l-sulfonamide (see, e.g., WO 2009/086835) (0.68g, 1.66.mmol), 2-fluoroethanol (0.12 ml, 1.99 mmol) and triphenphosphine (1.31 g, 4.99 mmol) were dissolved in THF, and diethyl azodicarboxylate (4.99 mmol) was added with stirring. Stirred at rt overnight, concentrated and purified by chromatography (petroleum ether:EtOAc 10-1 to 7-1) to afford compound 1.

¹H-NMR (CDCI₃) : δ 7.83 (m, 2H), 7.71 (m, 2H), 4.61 (dt, 2H), 3.86 (d, 2H), 3.70 (t, 2H), 3.53 (dt, 2H), 3.08 (m, 2H), 2.15-1.1 (m, 15 H), 0.98 (m, 2H).

Preparation 2: 5-amino-Λ/-(cvclohexylmethoxy)-Λ/-(2-fluoroethyl)pentane-l-sulfonamide (compound 2).

Compound 1 (0.76 g, 1.66 mmol) was dissolved in ethanol, hydrazine hydrate (0.40 ml, 8.3 mmol) was added and the mixture heated in a microwave oven at 12O⁰C for 20 min. The mixture was cooled to rt, filtered, the filtercake was washed with ethanol, the filtrate was concentrated and purified by chromatography (chloroform: methanol : NH₃ (25% aq.) 95:5:05) to afford compound 2.

¹H-NMR (CDCI₃) : δ 4.63 (dt, 2H), 3.88 (d, 2H), 3.60 (dt, 2H), 3.10 (m, 2H), 2.72 (t, 2H), 1.93 (m, 2H), 1.8-1.4 (m, 10 H), 1.23 (m, 3H), 1.00 (m, 2H).

Preparation 3: Λ/-(cvclohexylmethoxy)-7-(l,3-dioxoisoindolin-2-yl)-Λ/-(2-fluoroethyl)heptane- 1-sulfonamide (compound 3).

Λ/-(cyclohexylmethoxy)-5-(l,3-dioxoisoindolin-2-yl)heptane-l-sulfonamide (see, e.g., WO 2009/086835) (0.68g, 1.55. mmol), 2-fluoroethanol (0.11 ml, 1.86 mmol) and triphenphosphine (0.81 g, 3.1 mmol) were dissolved in THF, and diethyl azodicarboxylate (3.1 mmol) was added with stirring. Stirred at rt overnight, concentrated and purified by chromatography (petroleum ether: EtOAc 10-1 to 7-1) to afford compound 3. ¹H-NMR (CDCI₃) : δ 7.83 (m, 2H), 7.71 (m, 2H), 4.62 (dt, 2H), 3.87 (d, 2H), 3.67 (t, 2H), 3.54 (dt, 2H), 3.07 (m, 2H), 1.88 (m, 2H), 1.8-1.05 (m, 17 H), 0.99 (m, 2H).

Preparation 4: 7-amino-Λ/-(cvclohexylnnethoxy)-Λ/-(2-fluoroethyl)heptane-l-sulfonannide (compound 4).

Compound 3 (0.58 g, 1.21 mmol) was dissolved in ethanol, hydrazine hydrate (0.29 ml, 6.1 mmol) was added and the mixture heated in a microwave oven at 12O⁰C for 20 min. The mixture was cooled to rt, filtered, the filtercake was washed with ethanol, the filtrate was concentrated and purified by chromatography (chloroform: methanol : NH₃ (25% aq.) 95:5:05) to afford compound 4.

¹H-NMR (CDCI₃) : δ 4.63 (dt, 2H), 3.88 (d, 2H), 3.55 (dt, 2H), 3.08 (m, 2H), 2.68 (t, 2H), 1.90 (m, 2H), 1.8-1.05 (m, 17 H), 1.00 (m, 2H).

Examples

Example 1 : fE)-Λ/-cyclohexyl-Λ/-(2-morpholinoethoxy)-7-(3-pyridin-3- yl)acrylamido)heptanamide (compound 1001).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 7-amino-Λ/- cyclohexyl-Λ/-(2-morpholinoethoxy)heptanamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.73 (d, IH), 8.53 (dd, IH), 8.06 (dt, IH), 7.56 (d, IH), 7.49 (m, IH), 6.75 (d, IH), 4.09 (m, 3H), 3.71 (m, 4H), 3.34 (m, 2H), 2.67 (t, 2H), 2.56 (m, 4H), 2.50 (t, 2H), 1.9-1.5 (m, 11 H), 1.5-1.05 (m, 7H). Example 2: fE)-Λ/-(6-(Λ/-cvclohexylmethoxy)sulfamoyl)hexl-3-(pyridin-3-yl)acrylamide (compound 1002).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 6-amino-Λ/- (cyclohexylmethoxy)hexane-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.73 (d, IH), 8.53 (dd, IH), 8.07 (dt, IH), 7.57 (d, IH), 7.50 (m, IH), 6.75 (d, IH), 3.74 (d, 2H), 3.36 (t, 2H), 3.19 (m, 2H), 1.9-1.1 (m, 17 H), 0.98 (m, 2H).

Example 3: fE)-Λ/-(6-(cvclohexylmethoxy)-Λ/-(2-fluoroethyl)sulfamoyl)hexyl)-3-(pyridin-3- vDacrylamide (compound 1003).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 6-amino-Λ/- (cyclohexylmethoxy)-Λ/-(2-fluoroethyl)hexane-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.73 (d, IH), 8.53 (dd, IH), 8.07 (dt, IH), 7.57 (d, IH), 7.50 (m, IH), 6.75 (d, IH), 4.62 (dt, 2H), 3.88 (d, 2H), 3.55 (dt, 2H), 3.34 (t, 2H), 3.20 (t, 2H), 1.90 (m, 2H), 1.8-1.35 (m, 12H), 1.26 (m, 3H), 1.04 (m, 2H).

Example 4: fE)-Λ/-(6-(cvclohexylmethoxy)-Λ/-(2-morpholinoethyl)sulfamoyl)hexyl)-3-(pyridin- 3-yl)acrylamide (compound 1004).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 6-amino-Λ/- (cyclohexylmethoxy)-Λ/-(2-morpholinoethyl)hexane-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD) : δ 8.73 (d, IH), 8.53 (dd, IH), 8.07 (dt, IH), 7.57 (d, IH), 7.50 (m, IH), 6.75 (d, IH), 3.89 (d, 2H), 3.71 (m, 4H), 3.42 (t, 2H), 3.34 (t, 2H), 3.19 (m, 2H), 2.67 (t, 2H), 2.53 (m, 4H), 1.90 (m, 2H), 1.8-1.1 (m, 15 H), 1.04 (m, 2H).

Example 5: (D-Ethyl Λ/-cvclohexyl-P-(6-(3-pyridin-3-yl)acrylamido)hexyl)phosphonannidate (compound 1005).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and ethyl P-6- aminohexyl-Λ/-cyclohexylphosphonamidate (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.72 (d, IH), 8.53 (dd, IH), 8.07 (dt, IH), 7.57 (d, IH), 7.49 (m, IH), 6.76 (d, IH), 3.99 (m, 2H), 3.32 (m, 2H), 2.96 (m, IH), 1.87 (m, 2H), 1.8-1.05 (m, 21 H).

Example 6: (T)-/V-(6-(3,4-dihvdroisquinolin-2(lH)-ylsulfonyl)hexyl)-3-pyridin-3-yl)acrylamide (compound 1006).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 6-(3,4- dihydroisquinolin-2(lH)-ylsulfonyl)hexan-l-amine (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.72 (bs, IH), 8.53 (d, IH), 8.06 (d, IH), 7.56 (d, IH), 7.49 (m, IH), 7.15 (m, 4H), 6.74 (d, IH), 4.47 (s, 2H), 3.58 (t, 2H), 3.37 (m, 2H), 3.10 (t, 2H), 2.94 (m, 2H), 1.91 (m, 2H), 1.7-1.3 (m, 6 H). Example 7: fE)-Λ/-(5-(Λ/-cvclopentyl)-Λ/-(3-morholinopropyl)sulfamoyl)pentyl)-3-(pyridin-3- vOacrylamide (compound 1007).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 5-amino-Λ/- cyclopentyl-Λ/-(3-morpholinopropyl)pentan-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.74 (d, IH), 8.53 (dd, IH), 8.08 (dt, IH), 7.58 (d, IH), 7.50 (m, IH), 6.76 (d, IH), 4.07 (m, IH), 3.70 (m, 4H), 3.35 (t, 2H), 3.19 (m, 2H), 3.06 (m, 2H), 2.47 (m, 4H), 2.38 (t, 2H), 2.0-1.45 (m, 16 H).

[M + H] ⁺ = 493.3 [M-H + HCOOH]^~ = 437.5

Example 8 : fE)-Λ/-(5-(Λ/-cvclobutyl)-Λ/-(3-morholinopropyl)sulfamoyl)pentyl)-3-(pyridin-3- vDacrylamide (compound 1008).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 5-amino-Λ/- cyclobutyl-Λ/-(3-morpholinopropyl)pentan-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.74 (d, IH), 8.54 (dd, IH), 8.08 (dt, IH), 7.58 (d, IH), 7.50 (m, IH),

6.76 (d, IH), 4.22 (m, IH), 3.71 (m, 4H), 3.30 (m, 2H), 3.00 (m, 2H), 2.48 (m, 4H), 2.41 (t, 2H), 2.22 (m, 4H), 1.9-1.45 (m, 12 H).

[M + H] ⁺ = 479.3 [M-H + HCOOH]^"= 423.5

Example 9: (E)-Ethy\ morpholino(6-(3-(pyridin-3-yl)acrylamido)hexyl)phosphinate (compound 1009).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and ethyl 6- aminohexyl(morpholino)phosphinate (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.73 (d, IH), 8.54 (dd, IH), 8.08 (dt, IH), 7.57 (d, IH), 7.50 (m, IH), 6.76 (d, IH), 4.11 (m, 2H), 3.96 (m, 2H), 3.37 (m, 4H), 1.87 (m, 2H), 1.74 (m, 4H), 1.61 (m, 4H), 1.46 (m, 4H), 1.33 (t, 3 H).

[M + H] ⁺ = 410.2 [M-H + HCOOH]^~ = 454.3

Example 10: fE)-Λ/-(5-(Λ/-cvclobutyl-Λ/-(2-morholinoethoxy)sulfamoyl)pentyl)-3-(pyridin-3- vDacrylamide (compound 1010).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 5-amino-Λ/- cyclobutyl-Λ/-(2-morpholinoethoxy)pentan-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.74 (d, IH), 8.54 (dd, IH), 8.07 (dt, IH), 7.57 (d, IH), 7.50 (m, IH), 6.75 (d, IH), 4.25 (m, IH), 4.20 (m, 2H), 3.72 (m, 4H), 3.35 (m, 2H), 3.10 (m, 2H), 2.70 (m 2H), 2.57 (m, 4H), 2.41 (m, 2H), 2.16 (m, 2H), 1.91 (m, 2H), 1.75 (m, 2H), 1.60 (m, 4H).

[M + H] ⁺ = 481.3 [M-H + HCOOH]^"= 425.4

Example 11 : fE)-Λ/-(6-(Λ/-phenylsulfamoyl)hexyl)-3-(pyridin-3-yl)acrylamide (compound 1011).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 6-amino-Λ/- phenylhexane-1-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.72 (d, IH), 8.53 (dd, IH), 8.06 (dt, IH), 7.56 (d, IH), 7.49 (m, IH), 7.30 (m, 4H), 7.11 (m, IH), 6.74 (d, IH), 3.29 (m, 2H), 3.09 (m, 2H), 1.79 (m, 2H), 1.55 (m, 2H), 1.39 (m, 4H).

Example 12: fE)-Λ/-(6-(Λ/-(benzyloxy)-Λ/-methylsulfamoyl)hexyl)-3-(pyridin-3-yl)acrylamide (compound 1012).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 6-amino-Λ/- (benzyloxy)-Λ/-methylhexane-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.72 (d, IH), 8.52 (dd, IH), 8.05 (dt, IH), 7.56 (d, IH), 7.48 (m, IH), 7.38 (m, 5H), 6.75 (d, IH), 4.95 (m, 2H), 3.33 (m, 2H), 3.17 (m, 2H), 2.91 (s, 3H), 1.88 (m, 2H), 1.7-1.3 (m, 6H).

Example 13 : fE)-Λ/-(6-(Λ/-(benzyloxy)-Λ/-(2-morpholinoethyl)sulfamoyl)hexyl)-3-(pyridin-3- vDacrylamide (compound 1013).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 6-amino-Λ/- (benzyloxy)-Λ/-(morpholinoethyl)hexane-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.73 (d, IH), 8.53 (dd, IH), 8.05 (dt, IH), 7.57 (d, IH), 7.49 (m, IH), 7.39 (m, 5H), 6.74 (d, IH), 5.06 (s, 2H), 3.68 (m, 4H), 3.41 (t, 2H), 3.34 (m, 2H), 3.24 (m, 2H), 2.53 (t, 2H), 2.46 (m, 4H), 1.91 (m, 2H), 1.7-1.35 (m, 6H). Example 14: fE)-Λ/-(5-(Λ/-cvclopentyl-Λ/-(2-morholinoethoxy)sulfamoyl)pentyl)-3-(pyridin-3- vOacrylamide (compound 1014).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 5-amino-Λ/- cyclopentyl-Λ/-(2-morpholinoethoxy)pentan-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.73 (d, IH), 8.54 (dd, IH), 8.08 (dt, IH), 7.58 (d, IH), 7.50 (m, IH), 6.74 (d, IH), 4.21 (m, 2H), 4.05 (m, IH), 3.70 (m, 4H), 3.36 (m, 2H), 3.22 (m, 2H), 2.65 (m 2H), 2.54 (m, 4H), 2.0-1.5 (m, 14H).

Example 15: fE)-Λ/-(6-(Λ/-(4-chlorophenyl)-Λ/-methylsulfamoyl)hexyl)-3-(pyridin-3- vDacrylamide (compound 1015).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 6-amino-Λ/-(4- chlorophenyl)-Λ/-methylhexane-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.72 (d, IH), 8.52 (dd, IH), 8.05 (m, IH), 7.6-7.3 (m, 6H), 6.74 (d, IH), 3.30 (m, 2H), 3.10 (m, 2H), 3.32 (s, 3H), 1.78 (m, 2H), 1.57 (m, 2H), 1.43 (m, 4H).

Example 16: fE)-Λ/-(6-(Λ/-(4-chlorophenyl)-Λ/-(2-morpholinoethyl)sulfamoyl)hexyl)-3- (pyridin-3-yl)acrylamide (compound 1016).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 6-amino-Λ/-(4- chlorophenyl)-Λ/-(2-morpholinoethyl)hexane-l-sulfonamide (see, e.g., WO 2009/086835)

¹H-NMR (CD₃OD): δ 8.72 (d, IH), 8.53 (dd, IH), 8.05 (dt, IH), 7.56 (d, IH), 7.48 (m, IH), 7.44 (m, 4H), 6.74 (d, IH), 3.85 (t, 2H), 3.63 (m, 4H), 3.31 (m, 2H), 3.15 (m, 2H), 2.43 (m, 6H), 1.82 (m, 2H), 1.59 (m, 2H), 1.45 (m, 4H).

Example 17: fE)-Λ/-(6-(Λ/-cvclohexyl-Λ/-(2-morpholinoethoxy)sulfamoyl)hexyl)-3-(pyridin-3- vDacrylamide (compound 1017).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 6-amino-Λ/- cyclohexyl-Λ/-(2-morpholinoethoxy)hexane-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.73 (d, IH), 8.53 (dd, IH), 8.06 (dt, IH), 7.57 (d, IH), 7.49 (m, IH), 6.75 (d, IH), 4.15 (t, 2H), 3.70 (m, 4H), 3.58 (m, IH), 3.34 (m, 2H), 3.22 (bs, 2H), 2.64 (t 2H), 2.54 (t, 4H), 1.90 (m, 6H), 1.75-1.25 (m, HH), 1.18 (m, IH).

Example 18: fE)-Λ/-(7-(Λ/-cvclohexyl-Λ/-(2-morpholinoethoxy)sulfamoyl)heptyl)-3-(pyridin-3- vDacrylamide (compound 1018).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 7-amino-Λ/- cyclohexyl-Λ/-(2-morpholinoethoxy)heptane-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.73 (d, IH), 8.53 (dd, IH), 8.06 (dt, IH), 7.57 (d, IH), 7.49 (m, IH), 6.75 (d, IH), 4.15 (t, 2H), 3.70 (m, 4H), 3.58 (m, IH), 3.34 (m, 2H), 3.22 (bs, 2H), 2.64 (t 2H), 2.54 (t, 4H), 1.90 (m, 6H), 1.75-1.2 (m, 13H), 1.18 (m, IH).

Example 19: fE)-Λ/-(6-(Λ/-isopropyl-Λ/-(2-morpholinoethoxy)sulfamoyl)hexyl)-3-(pyridin-3- vDacrylamide (compound 1019).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 6-amino-Λ/- isopropyl-Λ/-(2-morpholinoethoxy)hexane-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.73 (d, IH), 8.53 (dd, IH), 8.06 (dt, IH), 7.57 (d, IH), 7.49 (m, IH), 6.75 (d, IH), 4.19 (t, 2H), 3.98 (m, IH), 3.71 (t, 4H), 3.34 (t, 2H), 3.23 (bs, 2H), 2.70 (t 2H), 2.59 (t, 4H), 1.89 (m, 2H), 1.7-1.35 (m, 6H), 1.29 (d, 6H).

Example 20: (T)-/V-(6-(morpholinosulfonyl))hexyl)-3-(pyridin-3-yl)acrylamide (compound 1020).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 6- (morpholinosulfonyl)hexan-l-amine (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.73 (d, IH), 8.53 (dd, IH), 8.06 (dt, IH), 7.57 (d, IH), 7.49 (m, IH), 6.75 (d, IH), 3.75 (m, 4H), 3.34 (m, 2H), 3.25 (m, 4H), 3.05 (m, 2H), 1.83 (m, 2H), 1.62 (m, 2H), 1.49 (m, 4H). Example 21 : r-r)-Λ/-(6-(nnorpholinosulfonvπ)hexyπ-3-(pyπdin-3-vπacrylannide (compound 1021).

¹H-NMR (CD₃OD): δ 8.73 (d, IH), 8.53 (dd, IH), 8.06 (dt, IH), 7.56 (d, IH), 7.49 (m, IH), 6.75 (d, IH), 4.10 (t, 2H), 3.36 (m, 4H), 3.21 (m, 2H), 1.87 (m, 4H), 1.70 (m, 2H), 1.61 (m, 2H), 1.49 (m, 4H).

Example 22: (T)-3-(pyridin-3-yl)-Λ/-(6-(pyrrolidin-l-ylsulfonyl)hexyl)acrylamide (compound 1022).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 6-(pyrrolidin-l- ylsulfonyl)hexan-l-amine (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.73 (d, IH), 8.53 (dd, IH), 8.06 (dt, IH), 7.56 (d, IH), 7.49 (m, IH), 6.75 (d, IH), 3.34 (m, 6H), 3.07 (m, 2H), 1.82 (m, 4H), 1.62 (m, 2H), 1.50 (m, 2H), 1.37 (m, 4H).

Example 23: f£>/V-(6-(azepan-l-ylsulfonyl)hexyl)-3-(pyridin-3-yl) acrylamide (compound 1023).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 6-(azepan-l- ylsulfonyl)hexan-l-amine (see, e.g., WO 2009/086835). ¹H-NMR (CD₃OD): δ 8.73 (d, IH), 8.53 (dd, IH), 8.06 (dt, IH), 7.57 (d, IH), 7.49 (m, IH), 6.75 (d, IH), 3.35 (m, 6H), 3.04 (m, 2H), 1.85-1.35 (m, 16H).

Example 24: f£>/V-(6-(piperidin-l-ylsulfonyl)hexyl)-3-(pyridin-3-yl) acrylamide (compound 1024).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 6-(piperidin-l- ylsulfonyl)hexan-l-amine (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.73 (d, IH), 8.53 (dd, IH), 8.06 (dt, IH), 7.57 (d, IH), 7.49 (m, IH), 6.75 (d, IH), 3.34 (m, 2H), 3.23 (m, 4H), 2.99 (m, 2H), 1.80 (m, 2H), 1.62 (m, 8H), 1.49 (m, 4H).

Example 25: fE)-Λ/-(4-(Λ/-cvclobutyl-Λ/-(3-morpholinopropyl)sulfamoyl)butyl)-3-(pyridin-3-yl) acrylamide (compound 1025).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 4-amino-Λ/- cyclobutyl-Λ/-(3-morpholinopropyl)butane-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD) : δ 8.73 (d, IH), 8.53 (dd, IH), 8.06 (dt, IH), 7.57 (d, IH), 7.49 (m, IH), 6.75 (d, IH), 4.21 (m, IH), 3.69 (t, 4H), 3.37 (t, 2H), 3.29 (t, 2H), 3.04 (t, 2H), 2.46 (t, 4H), 2.40 (t, 2H), 2.20 (m, 4H), 1.9-1.55 (m, 8H).

Example 26: fE)-Λ/-(4-(Λ/-cvclopentyl-Λ/-(3-morpholinopropyl)sulfamoyl)butyl)-3-(pyridin-3- yl) acrylamide (compound 1026).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 4-amino-Λ/- cyclopentyl-Λ/-(3-morpholinopropyl)butane-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.73 (d, IH), 8.53 (dd, IH), 8.06 (dt, IH), 7.57 (d, IH), 7.49 (m, IH), 6.75 (d, IH), 4.07 (m, IH), 3.68 (t, 4H), 3.38 (t, 2H), 3.18 (t, 2H), 3.09 (t, 2H), 2.45 (t, 4H), 2.37 (t, 2H), 1.95-1.45 (m, 4H).

Example 27: r-r)-Λ/-(5-(Λ/-(cvclohexylnnethoxy)sulfannoyl)pentyl)-3-(pyridin-3-yl)acrylamide (compound 1027).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 5-amino-Λ/- (cyclohexylmethoxy)pentane-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD): δ 8.71 (d, IH), 8.52 (dd, IH), 8.05 (dt, IH), 7.56 (d, IH), 7.48 (m, IH), 6.74 (d, IH), 3.74 (d, 2H), 3.35 (t, 2H), 3.21 (m, 2H), 1.9-1.45 (m, 12H), 1.24 (m, 3H), 0.98 (m, 2H).

Example 28: r-r)-Λ/-(7-(Λ/-(cvclohexylmethoxy)sulfamoyl)heptyl)-3-(pyridin-3-yl)acrylamide (compound 1028).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 7-amino-Λ/- (cyclohexylmethoxy)heptane-l-sulfonamide (see, e.g., WO 2009/086835). ¹H-NMR (CD₃OD): δ 8.72 (d, IH), 8.52 (dd, IH), 8.05 (dt, IH), 7.56 (d, IH), 7.48 (m, IH), 6.75 (d, IH), 3.74 (d, 2H), 3.33 (t, 2H), 3.18 (m, 2H), 1.9-1.1 (m, 17H), 0.98 (m, 2H).

Example 29: r-r)-Λ/-(5-(Λ/-(cyclohexylnnethoxy)-N-(2-fluoroethyl)sulfannoyl)pentyl)-3-(pyπdin- 3-yl)acrylamide (compound 1029).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and compound 2.

¹H-NMR (CDCI₃) : δ 8.71 (d, IH), 8.53 (dd, IH), 7.76 (dt, IH), 7.59 (d, IH), 7.29 (m, IH), 6.51 (d, IH), 6.30 (t, IH), 4.60 (dt, 2H), 3.85 (d, 2H), 3.52 (dt, 2H), 3.39 (q, 2H), 3.09 (t, 2H), 1.92 (m, 2H), 1.65 (m, 1OH), 1.18 (m, 3H), 0.96 (m, 2H).

Example 30: fE)-Λ/-(7-(Λ/-(cvclohexylmethoxy)-N-(2-fluoroethyl)sulfamoyl)heptyl)-3-(pyridin- 3-yl)acrylamide (compound 1030).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and compound 4.

¹H-NMR (CDCI₃) : δ 8.71 (d, IH), 8.53 (dd, IH), 7.76 (dt, IH), 7.58 (d, IH), 7.28 (m, IH), 6.52 (d, IH), 6.24 (t, IH), 4.60 (dt, 2H), 3.85 (d, 2H), 3.52 (dt, 2H), 3.36 (q, 2H), 3.06 (t, 2H), 1.86 (m, 2H), 1.8-1.3 (m, 14H), 1.17 (m, 3H), 0.96 (m, 2H).

Example 31 : (T)-/V-(6-(Λ/-(cvclohexylmethoxy)sulfamoyl)hexyl)-3-(pyridin-4-yl)acrylamide (compound 1031).

General procedure 1. Starting materials: (E)-3-(pyridyl-4-yl)acrylic acid and 6-amino-Λ/- (cyclohexylmethoxy)hexane-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CDCI₃) : 8.60 (m, 2H), 7.72 (bs, IH), 7.53 (d, IH), 7.34 (m, 2H), 6.60 (d, IH), 6.5 (t, IH), 3.80 (d, 2H), 3.37 (q, 2H), 3.19 (t, 2H), 1.81 (m, 2H), 1.8-1.05 (m, 15 H), 0.95 (m, 2H).

Example 32: fE)-Λ/-(6-(Λ/-(cvclohexyl-Λ/-(2-morpholinoethoxy)sulfamoyl)hexyl)-3-(pyridin-4- vDacrylamide (compound 1032).

General procedure 1. Starting materials: (E)-3-(pyridyl-4-yl)acrylic acid and and 6-amino-Λ/- cyclohexyl-Λ/-(2-morpholinoethoxy)hexane-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD) : 8.57 (m, 2H), 7.58 (m, 2H), 7.50 (d, IH), 6.85 (d, IH), 4.15 (t, 2H), 3.70 (t, 4H), 3.58 (m, IH), 3.35 (t, 2H), 3.23 (t, 2H), 2.64 (t, 2H), 2.54 (t, 4H), 1.90 (m, 6H), 1.75-1.2 (m, 13 H), 1.18 (m, IH).

Example 33: (T)-Λ/-(6-(morpholinsulfonyl)hexyl)-3-(pyridin-4-yl)acrylamide (compound 1033).

General procedure 1. Starting materials: (E)-3-(pyridyl-4-yl)acrylic acid and 6- (morpholinosulfonyl)hexan-l-amine (see, e.g., WO 2009/086835). ¹H-NMR (CDCI₃) : 8.60 (m, 2H), 7.53 (d, IH), 7.33 (m, 2H), 6.59 (d, IH), 6.04 (t, IH), 4.10 (t, 2H), 3.38 (m, 4H), 3.15 (t, 2H), 1.87 (m, 4H), 1.69 (m, 2H), 1.59 (m, 2H), 1.45 (m, 4H).

Example 34: fE)-Λ/-(6-(Λ/-(cvclohexylmethoxy)-Λ/-(2-morpholinoethyl)sulfamoyl)hexyl)-3- (pyridin-4-yl)acrylamide (compound 1034).

General procedure 1. Starting materials: (E)-3-(pyridyl-4-yl)acrylic acid and 6-amino-Λ/- (cyclohexylmethoxy)-Λ/-(2-morpholinoethyl)hexane-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD) : 8.57 (m, 2H), 7.58 (m, 2H), 7.51 (d, IH), 6.85 (d, IH), 3.89 (d, 2H), 3.71 (t, 4H), 3.42 (t, 2H), 3.35 (t, 2H), 3.20 (t, 2H), 2.67 (t, 2H), 2.53 (t, 4H), 1.90 (m, 2H), 1.8- 1.35 (m, 12 H), 1.26 (m, 3H), 1.04 (m, 2H).

Example 35: (T)-/V-(6-(Λ/-isopropyl-Λ/-(2-morpholinoethoxy)sulfamoyl)hexyl)-3-(pyridin-4- vDacrylamide (compound 1035).

General procedure 1. Starting materials: (E)-3-(pyridyl-4-yl)acrylic acid and 6-amino-Λ/- isopropyl-Λ/-(2-morpholinoethoxy)hexane-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD) : 8.58 (m, 2H), 7.58 (m, 2H), 7.51 (d, IH), 6.86 (d, IH), 4.18 (t, 2H), 3.98 (m, IH), 3.70 (t, 4H), 3.35 (t, 2H), 3.23 (bs, 2H), 2.66 (t, 2H), 2.55 (t, 4H), 1.89 (m, 2H), 1.7-1.35 (m, 6H), 1.29 (d, 6H).

Example 36: fE)-Λ/-(5-(Λ/-cvclopentyl-Λ/-(2-morpholinoethoxy)sulfamoyl)pentyl)-3-(pyridin-4- vDacrylamide (compound 1036).

General procedure 1. Starting materials: (E)-3-(pyridyl-4-yl)acrylic acid and 5-amino-Λ/- cyclopentyl-Λ/-(2-morpholinoethoxy)pentane-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD) : 8.57 (m, 2H), 7.57 (m, 2H), 7.51 (d, IH), 6.85 (d, IH), 4.20 (t, 2H), 4.03 (m, IH), 3.69 (t, 4H), 3.36 (t, 2H), 3.21 (bs, 2H), 2.64 (t, 2H), 2.53 (t, 4H), 2.0-1.5 (m, 14 H).

Example 37: fE)-Λ/-(4-(Λ/-cvclopentyl-Λ/-(3-morpholinopropyl)sulfamoyl)butyl)-3-(pyridin-4- vDacrylamide (compound 1037).

General procedure 1. Starting materials: (E)-3-(pyridyl-4-yl)acrylic acid and 4-amino-Λ/- cyclopentyl-Λ/-(3-morpholinopropyl)butane-l-sulfonamide (see, e.g., WO 2009/086835).

¹H-NMR (CD₃OD) : 8.58 (m, 2H), 7.58 (m, 2H), 7.51 (d, IH), 6.86 (d, IH), 4.07 (m, IH), 3.69 (t, 4H), 3.38 (t, 2H), 3.19 (t, 2H), 3.09 (t, 2H), 2.45 (t, 4H), 2.37 (t, 2H), 1.95-1.5 (m, 14 H).

Example 38: r-r)-Λ/-(5-(3-cvclohexyl-3-(2-morpholinoethoxy)ureido)pentyl)-3-(pyridin-3-yl) acrylamide (compound 1038).

General procedure 1. Starting materials: (E)-3-(pyridyl-3-yl)acrylic acid and 3-(5- aminopentyl)-l-cyclohexyl-l-(2-morpholinoethoxy)urea (see, e.g., PCT/EP2009/061200). ¹H-NMR (CD₃OD): δ 8.73 (d, IH), 8.53 (dd, IH), 8.06 (dt, IH), 7.57 (d, IH), 7.49 (m, IH), 6.75 (d, IH), 3.94 (bs, 2H), 3.84 (m, IH), 3.73 (m, 4H), 3.34 (m, 2H), 3.25 (t, 2H), 2.56 (m, 6H), 1.9-1.0 (m, 16H).

Example 39: In vitro cell proliferation assay (WST-I assay)

A2780 cells were seeded in 96-well plates at 3 x 10³ cells/well in 100 μl_ of culture medium, 8 wells were left empty for media only controls.

After 24 h the compound titrations were performed, in a separate dilution plate, by serially diluting the compounds of general formula (I) in culture medium. A 100 μl_ of each dilution was added to the plated cells, this was done in triplicate, and controls {e.g. DMSO and blanks) were included. The plates were incubated for 24 h at 37⁰C in a CO₂ incubator. The compound titrations were repeated in a separate dilution plate after 24 h. The media plus compound from the assay plates were then aspirated. A 100 μl_ of media was then added to all wells, followed by 100 μl_ of each compound dilution. The plates were incubated for a further 48 h at 37⁰C in a CO₂ incubator (total incubation time 72 h). The number of viable cells was then assessed using Cell Proliferation Reagent WST-I. 10 μl_ of WST-I reagent added to each well and incubated for one to four hours at 37⁰C in CO₂ incubator. The absorbance was measured (450 nm/690 nm).

The activity of compounds of general formula (I) in reducing the number of viable cells was calculated as:

% activity = [(S^c-B)/(S°-B)]xl00

S^c denotes signal measured in the presence of test compound, S⁰ denotes signal detected in the absence of compound, and B denotes background signal, measured in blank wells containing medium only. Analyse data using GraphPad Prism.

Results can be seen in Table 1.

Table 1 - In vitro cell proliferation assay (WST-I assay as described in Example 39)

Claims

1. A compound of the formula (I)

wherein

B is selected from a single bond and -O-;

D is selected from a single bond, -O-, -CR⁷R⁸- and -NR⁹-, wherein R⁷, R⁸ and R⁹ are independently selected from hydrogen, optionally substituted Ci-i₂-alkyl, optionally substituted Ci-i₂-alkenyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl;

R¹ and R² are independently selected from hydrogen, optionally substituted Ci-i₂-alkyl, optionally substituted C₃-i₂-cycloalkyl, -[CH₂CH₂O]i-i₀-(optionally substituted Ci-₆-alkyl), optionally substituted Ci_i₂-alkenyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; and R³ is selected from optionally substituted Ci_i₂-alkyl, optionally substituted C₃-i₂-cycloalkyl, -[CH₂CH₂O]i-i₀-(optionally substituted Ci-₆-alkyl), optionally substituted Ci_i₂-alkenyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; or R² and R³ together with the intervening atoms (i.e. -N-B-) form an optionally substituted N-containing heterocyclic or heteroaromatic ring; and

2. The compound according to claim 1, wherein X is pyrid-3-yl.

3. The compound according to claim 1, wherein X is pyrid-4-yl.

4. The compound according to any one of the preceding claims, wherein B is -O-.

5. The compound according to claim 4, wherein A is selected from -S(=O)₂- and -C(=O)-.

6. The compound according to any one of claim 1-3, wherein B is a single bond.

7. The compound according to claim 6, wherein A is selected from -S(=O)₂- and -C(=O)-.

8. The compound according to any one of the preceding claims, wherein D is a single bond.

9. The compound according to any one of the preceding claims, wherein m is an integer of 1- 8 and n is an integer of 0-3, wherein the sum m+n is 3-8.

10. The compound according to any one of the preceding claims, wherein at least one of R² and R³ includes a carbocyclic ring, heterocyclic ring or a heteroaromatic ring, or R² and R³ together with the intervening atoms form an optionally substituted N-containing heterocyclic or heteroaromatic ring.

11. The compound according to claim 10, wherein R² includes a carbocyclic ring.

12. The compound according to claim 1, wherein

A is selected from -C(=O)- and -S(=O)₂-;

B is -O-;

D is selected from a single bond and -O-,

m is an integer of 2-8 and n is 0; R² is selected from hydrogen, optionally substituted C₃-i₂-cycloalkyl, -[CH₂CH₂O]i-i₀- (optionally substituted Ci-₆-alkyl), -(CH₂)o-₂-(optionally substituted aryl), -(CH₂)₀-₂-(optionally substituted heteroaryl) and -(CH₂)₀-₂-(optionally substituted heterocyclyl);

R^4* is hydrogen.

13. The compound according to claim 1, which is selected from examples 1-38 described herein.

14. The compound according to any one of the preceding claims for use as a medicament.

15. The compound according to any one of the claims 1-13 for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT).

16. The compound according to claims 15, wherein said disease or condition is one or more selected from the group consisting of inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease, asthma and CPOD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukaemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, ataxia telengiectasia.

17. A method of inhibiting the enzymatic activity of nicotinamide phosphoribosyltransferase (NAMPRT) in a mammal, said method comprising the step of administering to said mammal a pharmaceutically relevant amount of a compound as defined in any of claims 1-13.

18. A method of treating a disease or condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT) in a mammal, said method comprising the step of administering to said mammal a pharmaceutically relevant amount of a compound as defined in any of claims 1-13.

19. The method according to claim 18, wherein the compound is administered in combination with a DNA damaging agent.

20. The method according to any one of the claims 18-19, wherein said disease or condition is one or more selected from the group consisting of inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukaemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, ataxia telengiectasia.